- FDA “Breakthrough Device Designation”
- Tox Study Completion
- WMIC 2019 Poster
- Q&A with Bob Proulx
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority